Perspective Therapeutics (CATX) Debt to Equity (2023 - 2026)

Perspective Therapeutics has disclosed Debt to Equity across 4 years of filings, most recently posting $0.0 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.0, down 20.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.0 (down 20.97% YoY), and the FY2025 annual result was $0.01, up 35.56% from the prior year.
• Debt to Equity came in at $0.0 for Q1 2026 at Perspective Therapeutics, down from $0.01 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.02 in Q4 2023 to a low of $0.0 in Q1 2026.
• The 4-year median for Debt to Equity is $0.01 (2025), against an average of $0.01.
• Across the five-year window, Debt to Equity tumbled 74.92% in 2024 and soared 35.56% in 2025, its largest moves.
• Perspective Therapeutics' Debt to Equity stood at $0.02 in 2023, then plunged by 74.92% to $0.01 in 2024, then surged by 35.56% to $0.01 in 2025, then plunged by 40.98% to $0.0 in 2026.
• The last three Debt to Equity figures came in at $0.0 (Q1 2026), $0.01 (Q4 2025), and $0.01 (Q3 2025), per Business Quant data.